Abstract:Over the last decade, more than 300 phase I and phase II gene-based clinical trials have been conducted worldwide for the treatment of cancer and monogenic disorders. Lately, these trials have been extended to the treatment of AIDS and, to a lesser extent, cardiovascular diseases. There are 27 currently active gene therapy protocols for the treatment of HIV-1 infection in the USA. Preclinical studies are currently in progress to evaluate the possibility of increasing the number of gene therapy clinical trials for cardiopathies, and of beginning new gene therapy programs for neurologic illnesses, autoimmuno diseases, allergies, regeneration of tissues, and to implement procedures of allogeneic tissues or cell transplantation. In addition, gene transfer technology has allowed for the development of innovative vaccine design, known as genetic immunization. This technique has already been applied in the AIDS vaccine programs in the USA. These programs aim to confer protective immunity against HIV-1 transmission to individuals who are at risk of infection. Research programs have also been considered to develop therapeutic vaccines for patients with AIDS and generate either preventive or therapeutic vaccines against malaria, tuberculosis, hepatitis A, B and C viruses, influenza virus, La Crosse virus, and Ebola virus. The potential therapeutic applications of gene transfer technology are enormous. However, the effectiveness of gene therapy programs is still questioned. Furthermore, there is growing concern over the matter of safety of gene delivery and controversy has arisen over the proposal to begin in utero gene therapy clinical trials for the treatment of inherited genetic disorders. From this standpoint, despite the latest significant achievements reported in vector design, it is not possible to predict to what extent gene therapeutic interventions will be effective in patients, and in what time frame.

Immune Modulation Strategies in Gene Therapy: Overcoming Immune Barriers and Enhancing Efficacy

Bioinspired and Biomimetic Gene Delivery Systems

Genetically modified immunomodulatory cell-based biomaterials in tissue regeneration and engineering

Strategies to Enhance the Therapeutic Efficacy, Applicability, and Safety of Genetically Engineered Immune Cells

CRISPR-Cas9 gene editing technology in human gene therapy: the new realm of medicine

Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care

CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future

Immunology of cell and gene therapy approaches for neurologic diseases

Engineering Gene Therapy: Advances and Barriers

Immune Responses to Viral Gene Therapy Vectors

Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system

Gene Therapy for Cancer: What Have We Done and Where Are We Going?

Gene Therapy Leaves a Vicious Cycle

Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications

A primer to gene therapy: Progress, prospects, and problems

Addressing the dark matter of gene therapy: technical and ethical barriers to clinical application

Gene knockout in cellular immunotherapy: Application and limitations

The era of bioengineering: how will this affect the next generation of cancer immunotherapy?

Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress

Clinical and Translational Landscape of Viral Gene Therapies

Therapeutic immunomodulation by rationally designed nucleic acids and nucleic acid nanoparticles